Sitemap - 2026 - The Billion Dollar Blindspot

The Billion Dollar Blind Spot Began in a Doctor’s Office

The Wealth-Health Convergence

UCB Just Paid $2.2 Billion for an Autoimmune Platform. The Indication List Tells You More Than the Deal Price.

The Future of Medicine Is Being Built on Incomplete Biology

Two Approved Drugs. The Same Structural Problem. What the Menopause Market Is Actually Telling Investors.

What Menopause Is Actually Doing to the Heart

Sun Pharma Agreed to Pay $11.75 Billion for Organon. The Portfolio Is Women's Health. The Thesis Is Not.

The Menopause Information Crisis

The Operation That Shouldn't Still Be Happening

Gilead Just Paid $5 Billion for a European Biotech. The Indication Was Ovarian Cancer. That's Not a Coincidence.

The Great Wealth Transfer and Women's Health: Why These Are the Same Story

Organon Is Telling You Exactly What It Is and the Exit Math for Women's Health Has Changed

Building FemTech Infrastructure in Asia

The Menopause Drug Market Just Split in Two and the Capital Opportunity Is Bigger Than Either Drug

When AI Gets It Right (and Wrong) on Women’s Health

📕I have news and it's been a long time coming!

The System That Ate Healthcare

Before Venture Shows Up | How Catalytic Capital Creates Women’s Health Markets

Why It Takes Years to Build in Women’s Health

Nobody Dies From Menopause

Why “Low Libido” Isn’t One Problem

Menopause is not shrinking your brain although the headlines want you to believe it is

Why Women’s Heart Disease Is Still Misdiagnosed

Why Fasting Feels Different in Midlife Women

The Myth of Safety: Why Cash Is Not Neutral After 40

How Hormones Change Women’s Hearts and Why Cardiology Wasn’t Built to See It

The Most Dangerous Moment for Wealth Is After You Have It